Credits: Canva
Breast cancer has quietly become one of India’s most pressing public health challenges. Today, it is the most commonly diagnosed cancer among Indian women and a leading cause of cancer-related deaths.
Data from the Global Cancer Observatory shows that nearly 1.9 lakh women are diagnosed with breast cancer in India each year. This works out to one new case every four minutes. The death toll is equally worrying. On average, a woman in India dies of breast cancer every eight minutes, highlighting how urgently the country needs stronger awareness, early diagnosis, and sustained care.
One factor that sets India apart is the age at which women are affected. Almost half of all breast cancer patients in the country are younger than 45. This is a much higher proportion than seen in many Western nations, where the disease is usually detected later in life.
Cancer surveillance data from GLOBOCAN and Indian registries under the Indian Council of Medical Research point to a steady rise in breast cancer cases. Rapid urbanisation, changing lifestyles, delayed pregnancies, shorter periods of breastfeeding, rising obesity, and limited screening practices have all played a role.
Late diagnosis continues to be one of the biggest challenges. Many women seek medical help only when the disease has progressed to advanced stages, making treatment more difficult and outcomes less certain. Fear, social stigma, lack of awareness, and limited access to screening services, especially in rural and semi-urban areas, often contribute to these delays.
For some women, the risk of recurrence can be significant, depending on the type and stage of cancer. Living with this uncertainty takes a lasting toll on mental and emotional wellbeing.
To address these gaps, Novartis has launched the ‘Take Charge’ campaign in collaboration with Times Network. The initiative aims to move the conversation beyond diagnosis and medication, encouraging women and their families to play an active role in decisions about care, recovery, and quality of life.
Speaking at the Times Network India Health Summit and Awards 2025, Amitabh Dubey, Country President and Managing Director of Novartis India, underlined that effective cancer care goes far beyond medicines alone. He spoke about the need for personalised treatment, open conversations between doctors and patients, and long-term support throughout the cancer journey.
According to Amitabh Dubey, advances in medical science have changed the way many cancers are managed. In breast cancer, better imaging, improved diagnostics, genomics, and targeted therapies now allow doctors to tailor treatment to the biology of each patient rather than relying on a uniform approach.
Awareness remains a central pillar of the ‘Take Charge’ initiative. Many women hesitate to speak openly about breast health or postpone seeing a doctor even after noticing symptoms. Encouraging routine self-examinations, timely screenings, and honest conversations about warning signs is especially important for younger women, who may not believe they are at risk.
The campaign also places strong emphasis on caregivers and families. Emotional support, access to reliable information, and timely medical advice can make a meaningful difference to both treatment outcomes and recovery.
Although government schemes such as Ayushman Bharat and various state cancer programmes have improved access to care, health insurance coverage in India remains limited, reaching only about 38 percent of the population. As a result, newer and more advanced treatments are still beyond the reach of many patients.
Novartis has been working with government agencies and local health systems to improve referral pathways, strengthen early detection efforts, and train frontline health workers. Community-based initiatives involving ASHA workers, awareness drives, and structured referrals aim to ensure that women with early symptoms reach appropriate care without unnecessary delays.
Breast cancer does not have to signal the end of a woman’s life or identity. With early diagnosis, personalised treatment, and continued support, many women go on to live full and meaningful lives. Campaigns like Take Charge seek to reinforce this message and remind women that they can remain active decision-makers in their own health journeys.
As Amitabh Dubey noted at the launch, taking charge is not only about fighting disease. It is about having the knowledge, confidence, and support to ask the right questions, make informed choices, and live well beyond cancer.
Credit: iStock
In a landmark judgement, the Supreme Court today allowed passive euthanasia for a 32-year-old man, living in a vegetative state for the last 13 years.
A bench comprising Justice JB Pardiwala and Justice KV Viswanathan allowed the withdrawal of life support for Harish Rana, a resident of Ghaziabad, who has been in a coma and kept alive on tubes for breathing and nutrition after sustaining severe head injuries following a fall from a building in 2013 in Chandigarh.
It is the first known case of a court-ordered passive euthanasia in India, since it was legalised in 2018 and modified in 2023, recognizing the fundamental right to die with dignity.
"Harish Rana, presently aged 32 years, was once a young, bright boy. He met with a tragic life-altering accident after a fall from the fourth floor of his paying guest accommodation. His brain injury left him in a condition of Persistent Vegetative State (PSV) with 100 percent quadraplegia... Medical reports show that his medical condition has not improved in the past 13 years," LiveLaw quoted the bench as saying.
The Court noted that the continuation of his treatment -- Clinically Administered Nutrition (CAN) via surgically installed PEG tubes -- can just prolong his biological existence but will not lead to any therapeutic improvement.
Harish was a BTech student in Chandigarh who suffered severe traumatic brain injury after falling from the fourth floor of his paying guest accommodation in August 2013.
Since then, he has remained bedridden and dependent on others for all activities of daily life.
Harish's father, the petitioner, first approached the Delhi High Court in 2024, seeking permission for passive euthanasia, but was rejected as the patient was not terminally ill.
The same year, the petitioner knocked on the doors of the Supreme Court, which, though it refused to entertain the plea, directed the Uttar Pradesh government to bear the treatment expenses.
In 2025, the petitioner filed a miscellaneous application in the Supreme Court, noting that Harish's condition had no scope for improvement.
The Court then directed the constitution of a Primary Medical Board led by the District Hospital in Noida to examine his health, as well as a Secondary Medical Board constituted by the All India Institute of Medical Sciences (AIIMS).
After perusing the report, Justice Pardiwala remarked that it's a "sad report" and the man can't continue to live like this. Before passing the final order, the Court met the parents, LiveLaw reported.
The Court has asked AIIMS to provide palliative care, so that the withdrawal of CAN can be given effect to.
To maintain the dignity of death, the apex Court said that the life support must be withdrawn with a tailored plan.
In 2018, a five-judge Constitution Bench had recognized and given sanction for passive euthanasia, and living will/advance directives.
Later in 2023, the SC modified the guidelines, noting that withdrawal of life support is permissible only after the approval of the Primary and Secondary Medical Boards.
With the Harish Rana judgment, the apex Court today clarified how passive euthanasia should be applied in cases where a patient’s life is being supported by feeding tubes.
The top Court waived off the reconsideration period of 30 days and noted that the medical treatment, including the CAN administered to the patient, can be withdrawn or withheld.
Passive Euthanasia allows a terminally ill or irreversibly comatose patient to die naturally. It involves deliberately withholding or withdrawing life-sustaining treatments (like ventilators, feeding tubes, or medication). It has been legal since 2018, but under strict guidelines.
In Active Euthanasia, patients are administered a lethal injection to cause death. It is illegal in India and considered an offence.
The Aruna Shanbaug case in 2011 opened the door for passive euthanasia in India for the first time.
The top Court rejected euthanasia in the case of Shanbaug, a nurse at Mumbai's KEM hospital who was in a vegetative state for 42 years after an assault in 1973, as the hospital staff who cared for her for decades did not support stopping treatment.
Shanbaug continued to be under care and passed away naturally in 2015
However, in her case, the court made the judgment allowing for passive euthanasia in certain rare situations under strict conditions.
Credit: iStock
About 6 million people in India's capital city are living with several vision problems, such as poor distance vision or near vision, according to a recent study by doctors at All India Institute of Medical Sciences (AIIMS), New Delhi.
The study, Dr. Rajendra Prasad Centre for Ophthalmic Sciences at AIIMS, and submitted to the World Health Organization (WHO), also flagged major gaps in eye care services in Delhi, the Times of India reported.
An estimated one-third of the population in the national capital was identified with refractive errors or presbyopia -- conditions that can usually be corrected with a pair of glasses. Globally, 826 million people suffer from presbyopia.
About 70 percent of older adults in the capital city were identified with the problem.
Alarmingly, about 13.1 percent school-going children had refractive errors, Dr. Praveen Vashist, professor and head of community ophthalmology at AIIMS, was quoted as saying.
The study showed a lack of access to vision correction. While just 60 percent of people needing distance vision correction could access care, those with near vision correction could access care in over 47 percent of cases.
Further, the doctors found:
But Dr. Vashisth noted that Delhi currently has only 1,085 ophthalmologists and approximately 489 optometrists.
Further, only 50 community-level vision centers, out of the has 249 eye care institutions in the city were found to be functioning. Moreover, only about 25 percent of children were receiving free spectacles through public health initiatives.
According to the World Health Organization (WHO), at least 2.2 billion people worldwide have near or distance vision impairment. Of these, at least 1 billion cases could be prevented with increased access to eyeglasses and cataract surgeries
The WHO identifies refractive errors and cataracts as the leading causes of vision impairment and blindness.
Vision loss can affect people of all ages; however, most people with vision impairment and blindness are over the age of 50.
Here's how to maintain a healthy vision:
Credits: iStock
Ibuflam tablets by pharmaceutical manufacturer Zentiva under the brand name Lichtenstein has been recalled. The 600mg tablets of ibuprofen products were recalled due to contamination. As per several media reports, a piece of metal was found in the tablet which triggered the recall. As per the manufacturer, the affected tablet are the 50-tablet packs with the batch number 5R02514.
Zentiva stated that the recall is explicitly directed at wholesalers and pharmacies, as the company confirmed upon request and the recall is not directed on patients. This measure was taken as a precautionary measure and in consultation with the relevant regulatory authorities.
As of now, patients have the option to return packages from the affected batch and receiving a replacement.
Also Read: Leucovorin Approved By FDA But For A Rare Genetic Disease, Not For Autism
As per Zentiva, the standard procedure of returning packages from the affected batch and receiving a replacement could be availed. For instance, if the package is almost empty, the standard procedure does not need to be followed, as this could potentially be considered a new prescription. However, patients will have the option of returning packages with the batch number.
A Zentiva spokesperson explained, "The possibility of obtaining a replacement through the supplying pharmacy in case of suspected quality defects always exists. Any connection to the recall lies solely in the fact that the suspicion regarding this batch can generally be considered justified."
This is not a case of re-dispensing under the replacement procedure. It is important to note that when a replacement pack is dispensed in response to a quality complaint, the affected medicinal product is not being placed on the market again, but rather a previously prescribed and supposedly defective medicinal product is being replaced.
Read: THIS Alternative Could Help Prevent Gut Damage Caused By Painkillers
Ibuprofen is a nonsteroidal anti-inflammatory drug or NSAID that is used to relieve pain, fever, and inflammation. Ibuflam is a brand name which is a combination medication containing ibuprofen and paracetamol or acetaminophen, which is also designed for enhanced pain relief.
As per the World Health Organization (WHO), ibuprofen is on the list of essential medication. The medicine is used by mouth as a syrup or tablet, and could also be applied directly to the skin as a mousse, gel, or spray.
The medicine could have some side effects, which could include pain, diarrhea or constipation, nausea and vomiting, dyspepsia, bloating, dizziness, headache, nervousness, skin rash, tinnitus, edema or fluid retention.
OR
© 2024 Bennett, Coleman & Company Limited